Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MELK drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MELK Recombinant Protein High purity (>95%), Endotoxin Controlled, Sequence Verified. Suitable for kinase assays. |
View MELK Products |
| Gene Delivery | MELK Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and overexpression studies. |
View MELK Products |
| Benchmark Ab | Anti-MELK Recombinant Antibody Recombinant positive control for Western Blot, IHC, and IP. |
View MELK Products |
| Validator | MELK siRNA Set For knockdown verification and target validation assays. |
View MELK Products |
| Related Target A | AMPK Subfamily off-target screening to ensure kinase inhibitor selectivity. |
View AMPK Products |
| Related Target B | PLK1 Synergistic cell cycle regulator frequently co-targeted in aggressive oncology models. |
View PLK1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Target Validation & Off-target Controversy | Sequence-verified siRNA sets and knockout-validated controls to confirm target dependency. |
| Kinase Profiling & Selectivity Screening | High-purity WT MELK recombinant proteins alongside closely related AMPK subfamily proteins. |
| Lack of Controls | Clinical-grade benchmark antibodies and recombinant positive controls included |
| False Positives in Phenotypic Screening | Validated siRNA included for specificity checks in cell-based assays |
Live MELK R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for MELK therapeutics is intensifying, with major players shifting focus from traditional small-molecule kinase inhibitors to selective degraders (PROTACs) and combination regimens. As first-generation therapies like OTSSP167 reach advanced clinical evaluation, the next wave of R&D is targeting highly selective, non-off-target profiles to overcome past clinical toxicities associated with multi-kinase inhibition.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitors | OncoTherapy Science, University of Chicago | TNBC, Glioblastoma, Lung Cancer | Selectivity Assay (Need Mutant vs WT Proteins & AMPK homolog panels) |
| PROTACs / Degraders | Academic Research Institutes, Biotech Startups | Hematological Malignancies, Solid Tumors | Degradation Kinetics Validation (Need High-purity MELK & CRISPR/siRNA tools) |
| RNA Therapeutics | Preclinical candidates | Refractory Solid Tumors | Knockdown Efficiency Verification (Need Lentivirus & siRNA sets) |